Demographic representation in Phase III clinical trials of anti‐amyloid therapy for Alzheimer’s disease: a cross‐sectional analysis

Our results suggest that Caucasian individuals are overrepresented, while Black and Hispanic individuals are underrepresented in all anti-amyloid trials for Alzheimer's disease to date. The current evidence base for anti-amyloid therapy for AD does not proportionately reflect the racial and ethnic demographics of disease burden. Future trials should aim to proactively recruit from underrepresented racial groups to ensure these drugs are demonstrated as safe and effective in the whole spectrum of the patient population.